AusAm Biotechnologies

AusAm Biotechnologies was a medical diagnostic company specializing in the early detection of chronic kidney disease (CKD) and diabetic nephropathy. The company's core technology focused on the discovery that standard clinical assays fail to detect a significant portion of urinary albumin, termed "non-immunoreactive albumin." By utilizing high-performance liquid chromatography (HPLC) through their Accu-Albumin test, AusAm provided a more comprehensive assessment of renal health than traditional dipstick or immunoassay methods. This technology was designed to identify patients at risk of kidney failure years earlier than conventional tests, enabling proactive therapeutic intervention. The company primarily served the nephrology and endocrinology markets before ceasing active operations.